Supernus Pharmaceuticals Inc.

SUPN | NASDAQ

$43.66

+$0.88 (+2.06%)

Sep 22, 2026, 2:11 PM ET · Market open

Fiscal Year Period Ending	FY 2025 Dec 30, 2025	FY 2024 Dec 30, 2024	FY 2023 Dec 30, 2023	FY 2022 Dec 30, 2022	FY 2021 Dec 30, 2021	FY 2020 Dec 30, 2020
Revenue	718.95M	661.82M	607.52M	667.24M	579.78M	520.4M
Cost of Revenue	74.56M	77.91M	83.78M	87.22M	75.06M	52.46M
Gross Profit	644.39M	583.91M	523.74M	580.02M	504.71M	467.94M
Operating Income	-36.86M	81.67M	-5.27M	46.12M	86.03M	173.7M
Interest Income	13.25M	16.2M	10.45M	21.69M	10.57M	18.7M
Pretax Income	-49.03M	97.87M	2.77M	60.74M	73.18M	168.65M
Net Income	-38.55M	73.87M	1.32M	60.71M	53.42M	126.95M
Selling & General & Admin	485.56M	335.78M	336.36M	377.22M	304.76M	200.68M
Research & Development	106.24M	108.8M	91.59M	74.55M	90.47M	75.96M
Other Expenses	89.46M	57.67M	101.06M	82.12M	23.46M	17.6M
Operating Expenses	681.25M	502.25M	529.01M	533.89M	418.69M	294.24M
Interest Expense	n/a	n/a	2.42M	7.07M	23.42M	23.75M
Selling & Marketing Expenses	288.65M	88.5M	99.7M	267.79M	199.71M	134.75M
Cost & Expenses	755.82M	580.15M	612.79M	621.11M	493.75M	346.7M
Income Tax Expense	-10.48M	24.01M	1.45M	32K	19.75M	41.7M
Shares Outstanding (Basic)	56.45M	55.1M	54.54M	53.67M	53.1M	52.62M
Shares Outstanding (Diluted)	56.45M	55.96M	55.51M	61.68M	54.36M	53.69M
EPS (Basic)	-0.68	1.34	0.02	1.13	1.01	2.41
EPS (Diluted)	-0.68	1.32	0.02	1.04	0.98	2.36
EBITDA	42.53M	178.28M	90.04M	153.36M	129.19M	210.54M
EBIT	-49.03M	97.87M	5.18M	67.81M	96.6M	192.4M
Depreciation & Amortization	91.56M	80.41M	84.86M	85.54M	32.6M	18.14M